Sales Growth Analysis: The Silvercorp Metals Inc. (SVM), Sarepta Therapeutics Inc. (SRPT)

You should consider shares of Silvercorp Metals Inc. (NYSE:SVM) and Sarepta Therapeutics Inc. (NASDAQ:SRPT) if you are looking for a great stocks to invest in. Starting with the SVM shares, which traded at $5.60 at the close of the recent session, gaining 2.75%. On Wednesday, the company’s shares shed $0.15 from its value which represented in intraday trading. The stock is now -1.23% lower in year-to-date (YTD) trading. SVM’s intraday high was $5.63 while its lowest price touched $5.47. The stock’s 52-week high price is $5.93, which means the current price is at -5.56%. In terms of trading activity, the daily trading volume fell to 1059164 against 200-day average trading volume of 1,067,417 shares.

What are analyst forecasts for Silvercorp Metals Inc. (NYSE:SVM)?

At a consensus rating of 4.33, SVM is trending as a streaking Moderate Buy, as it has been the case a month ago when 3 analysts called it a Moderate Buy. Two months ago, 2 analysts recommended, on average, that SVM stock is a Moderate Buy. The Basic Materials company’s shares’ overall bullish trend saw it close lower on Wednesday compared to its opening price of $5.50 on the day.

Forecasts for Silvercorp Metals Inc. (NYSE:SVM) give the stock a fair value for the growth of -22.54% from its last price. The 12-month price forecast for the stock by analysts puts the stock’s mean price target at $4.57, which means the price per share could fall by nearly -$1.03. The price range target is between a low of $3.97 and a high of $5.50. The stock would need to loss by about $-1.82 to hit the estimated high or 0.35% from its 12-month low.

Silvercorp Metals Inc. (NYSE:SVM) Upgrades and Downgrades

In terms of rating changes, Alliance Global Partners on November 12, 2019, Downgrade Silvercorp Metals Inc. (SVM) at Neutral. They believe the stock could reach $4.35 in the near term. Analysts at BMO Capital Markets have assigned a Market Perform rating for the stock in their research note on September 11, 2019. Moreover, ROTH Capital analysts issued a rating of Buy for the stock on August 29, 2017.

Sarepta Therapeutics Inc. (NASDAQ:SRPT) adds $2.31 on Wednesday

The SRPT stock has risen 0.93% year-to-date and is currently trading at $130.24, which is -17.98% below its 52-week high. The company shares gained 1.81% on the day and have risen nearly 80.76% off a low hit. At current levels, Sarepta Therapeutics Inc. has a valuation of about $365.10M. As of 01/15/20, this stock has risen 0.16% during the week and closed at $127.93 in the previous session. However, recent Sarepta Therapeutics Inc. stock performance shows that SRPT shares are -1.37% down over the last month, and 47.92% up for the last three months.

Earnings per share (EPS) estimates for the current quarter are -$1.02, with the trailing 12-month share earnings at -$8.56. The ratio is expected to be down by -54.60% for the current year 2019 and 30.90% for next year. Over the next 5-year period, earnings per share will be -0.20%. But will the SRPT stock surprise in the current quarter results, where the -$1.7 actual EPS reported on 9/29/2019 surprised by -25.90% or was lower by -$0.35 from the estimated -$1.35.

Sales Growth to climb 63.40% for the year

How well will Sarepta Therapeutics Inc. perform as a business over the current quarter, year and next 5-year period? Compared to the year-ago quarter, analysts forecast the company to bring in between $91.8M and $103M in current quarter sales. The consensus estimated for the current quarter is $98.39M from sales. Forecasts for this fiscal year are between $365.8M and $383.72M and the consensus estimate for sales is at $378.22M. SRPT has its next quarter sales estimates at between $99M and $164.41M, with the quarter-over-quarter growth estimates at 33.60% and the annual growth forecast for the year at 63.40%.

Who owns shares in Sarepta Therapeutics Inc. (SRPT)?

Let’s briefly focus on the share ownership of the Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock, where we find that 99.30% of shares are held by institutions. FMR, LLC tops the list of institutional owners as it is holding 8.06 million shares or 10.82% of shares outstanding. Vanguard Group, Inc. (The) and Blackrock Inc. held 6.37 million and 4.51 million representing 8.54% and 6.04% respectively at the close of the last trading session. As of Sep 29, 2019, Sands Capital Management, Inc. accounted for 3.95 million shares at over 297.67 million. This represented 5.30% of shares outstanding. Price (T.Rowe) Associates Inc held 3.79 million shares at over 285.32 million representing 5.08% of shares outstanding.

SRPT Insider Activity

Insider activity can also give a signal in terms of price direction. Looking at Sarepta Therapeutics Inc. (SRPT), a total of 270000 shares have been sold by insiders over the last 6 months while 463986 shares were added in the same time span. On 12/13/2019, CFO, CBO & Executive Vice President by the name Mahatme Sandesh sold 125000.0 shares worth $15.7 million at the price of $125.50 per share. Filings also show that Howton David Tyronne Jr sold a total of 78000.0 shares on 12/13/2019 valued at $9.8 million. Since the last insider activity, the company’s share price has dropped -1.37%.